Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENG-E2 is a combination drug consisting of etonogestrel (a progestin) and 17β-estradiol (a natural estrogen), formulated as a contraceptive vaginal ring. The mechanism of action involves suppression of ovulation through inhibition of gonadotropin secretion by the pituitary gland, primarily via negative feedback on the hypothalamic-pituitary-gonadal axis. Etonogestrel acts as a progestin to inhibit ovulation and thicken cervical mucus, while estradiol provides estrogenic activity to stabilize the endometrium and reduce breakthrough bleeding. The product was developed for use in women of reproductive age for contraception[1][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENG-E2.